Citizens reiterates Spruce Biosciences stock rating on therapy lead

Citizens has kept its Market Outperform rating on Spruce Biosciences (NASDAQ:SPRB) stock, with the stock valued at $144.00 per share. Despite the stock's recent drop of 8% to $49.41, it has still managed a notable 492% return over the last year, despite the volatility. The company's focus on therapeutic development for rare diseases, particularly its leading emerging therapy TA-ERT for MPS IIIB, was highlighted at the recent virtual Advance Sanfilippo Community Conference.

The firm's rating suggests that Spruce Biosciences is expected to outperform the average return of the stocks they cover. Analysts have supported this rating through a risk-adjusted discounted cash flow analysis, indicating the company's strong position in the market.